BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Chen YX, Yang P, Du SS, Zhuang Y, Huang C, Hu Y, Zhu WC, Yu YY, Liu TS, Zeng ZC. Stereotactic body radiotherapy combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma: A phase II clinical trial. World J Gastroenterol 2023; 29(24): 3871-3882 [PMID: 37426321 DOI: 10.3748/wjg.v29.i24.3871]
URL: https://www.wjgnet.com/1007-9327/full/v29/i24/3871.htm
Number Citing Articles
1
Ajay Patel. Stereotactic Body Radiation Therapy Combined With Immunotherapy for Patients With Hepatocellular Carcinoma‐A ReviewLiver International Communications 2024; 5(4) doi: 10.1002/lci2.70005
2
P.P. Sorochan, N.E. Prokhach, A.M. Nasonova, І.S. Hromakova, S.V. Artiukh, І.А. Hromakova. Immune checkpoint inhibitors and radiotherapy in gastrointestinal cancer treatmentУкраїнський радіологічний та онкологічний журнал 2024; 32(2): 244 doi: 10.46879/ukroj.2.2024.244-266
3
Clayton T. Marcinak, Patrick B. Schwartz, Mustafa M. Basree, Newton Hurst, Michael Bassetti, Jeremy D. Kratz, Nataliya V. Uboha. Treatment of Oligometastatic GI CancersAmerican Society of Clinical Oncology Educational Book 2024; 44(1) doi: 10.1200/EDBK_430152
4
Caressa Hui. Role of Local Therapy for Metastatic Gastrointestinal MalignanciesDigestive Disease Interventions 2024;  doi: 10.1055/s-0044-1800822
5
Seo Hee Choi, Byung min Lee, Jina Kim, Do Young Kim, Jinsil Seong. Efficacy of stereotactic ablative radiotherapy in patients with oligometastatic hepatocellular carcinoma: A phase II studyJournal of Hepatology 2024; 81(1): 84 doi: 10.1016/j.jhep.2024.03.003
6
Pei Zhang, Chenyan Zhang, Xiaoying Li, Chen Chang, Cailing Gan, Tinghong Ye, Dan Cao. Immunotherapy for gastric cancer: Advances and challengesMedComm – Oncology 2024; 3(4) doi: 10.1002/mog2.92
7
Hao Su, Yongguang Wei, Xiwen Liao, Guangzhi Zhu, Minhao Peng, Fang Fan, Tao Peng. Interpretation of the updates of the chinese guidelines for the diagnosis and treatment of primary liver cancer (CNLC-2024 Edition)Hepatoma Research 2024;  doi: 10.20517/2394-5079.2024.70
8
Zhan Shi, Sihui Zhu, Yuncheng Jin, Liang Qi, Mingzhen Zhou, Ziyan Zhou, Juan Zhang, Baorui Liu, Jie Shen. Lymphocyte-to-C Reactive Protein Ratio is an Independent Predictor of Survival Benefits for Hepatocellular Carcinoma Patients Receiving RadiotherapyJournal of Hepatocellular Carcinoma 2024; : 305 doi: 10.2147/JHC.S452424
9
Leonardo Stella, Clemence Hollande, Yasmina Ben Merabet, Hugo Fakhouri, Vincent Leclerc, Francesca Romana Ponziani, Mohamed Bouattour. Promising PD-1 antagonists for liver cancer: an evaluation of phase II and III resultsExpert Opinion on Emerging Drugs 2024; 29(4): 369 doi: 10.1080/14728214.2024.2430493
10
Rahul Khandekar, Sabi Shrestha, Kawika Dipko, Colleen Conger, Neil B. Newman. Viral-Mediated Hepatocellular Carcinoma: A Review on Mechanisms and Implications for TherapyApplied Radiation Oncology 2024; 13(3): 15 doi: 10.37549/ARO-D-24-00019
11
Tong Liu, Guorui Meng, Shihui Ma, Junqi You, Liang Yu, Risheng He, Xudong Zhao, Yunfu Cui. Progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinomaFrontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1455716